Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HPV bivalent (types 16, 18) vaccine
- Development stage
- Unknown
- Lead developer
- Walvax Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HPV bivalent (types 16, 18) vaccine is a recombinant vaccine designed to prevent infections caused by Human Papillomavirus (HPV) types 16 and 18. These two HPV types are responsible for a significant majority of cervical cancer cases and other HPV-related diseases. The vaccine contains non-infectious virus-like particles (VLPs) composed of the L1 capsid proteins from HPV types 16 and 18. Upon administration, these VLPs stimulate the immune system to produce protective antibodies, thereby conferring immunity against future infections by these specific HPV types. Examples include Walrinvax, developed by Shanghai Zerun Biotechnology Co.,Ltd., and Cervarix, developed by GlaxoSmithKline.
- Brand names
- WalrinvaxCervarixCecolin
- Other names
- Recombinant Human Papillomavirus Virus-like Particle Vaccine (Type 16 and 18 L1 Proteins, Yeast)Human Papillomavirus Bivalent (Types 16 and 18) Vaccine, RecombinantBivalent Human Papillomavirus Vaccine
02
Targets
HPV18 L1HPV16 (Human papillomavirus type 16)
Beyond the preview
Go deeper on HPV bivalent (types 16, 18) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HPV bivalent (types 16, 18) vaccine.